Cocaine Self-Administration Elevates GluN2B Within DmPFC Mediating Heightened Cue-Elicited Operant Responding
Overview
Authors
Affiliations
Cue-elicited drug-craving correlates with hyperactivity within prefrontal cortex (PFC), which is theorized to result from dysregulated excitatory neurotransmission. The NMDA glutamate receptor is highly implicated in addiction-related neuroplasticity. As NMDA receptor function is regulated critically by its GluN2 subunits, herein, we assayed the relation between incubated cue-elicited cocaine-seeking following extended access to intravenous cocaine (6 h/d; 0.25 mg/infusion for 10 d) and the expression of GluN2A/B receptor subunits within PFC sub regions during early versus late withdrawal (respectively, 3 vs. 30 days). Cocaine-seeking rats exhibited elevated GluN2B expression within the dorsomedial aspect of the PFC (dmPFC); this effect was apparent at both 3 and 30 days withdrawal and occurred in cocaine-experienced rats, regardless of experiencing an extinction test or not. Thus, elevated dmPFC GluN2B expression appears to reflect a pharmacodynamic response to excessive cocaine intake that is independent of the duration of drug withdrawal or re-exposure to drug-taking context. The functional relevance of elevated dmPFC GluN2B expression for drug-seeking was assessed by the local infusion of the prototypical GluN2B-selective antagonist ifenprodil (1.0 µg/side). Ifenprodil did not alter cue-elicited responding in animals with a history of saline self-administration. In contrast, ifenprodil lowered cue-elicited cocaine-seeking, while potentiating cue-elicited sucrose-seeking. Thus, the effects of an intra-dmPFC ifenprodil infusion upon cue reactivity are reinforcer-specific, arguing in favor of targeting GluN2B-containing NMDA receptors as a pharmacological strategy for reducing behavioral reactivity to drug-associated cues with the potential benefit of heightening the reinforcing properties of cues associated with non-drug primary rewards.
Towers E, Shapiro D, Abel J, Bakhti-Suroosh A, Kupkova K, Auble D Biol Psychiatry Glob Open Sci. 2023; 3(4):734-745.
PMID: 37881559 PMC: 10593899. DOI: 10.1016/j.bpsgos.2023.01.007.
Towers E, Kilgore M, Bakhti-Suroosh A, Pidaparthi L, Williams I, Abel J Front Behav Neurosci. 2023; 16:1027310.
PMID: 36688133 PMC: 9854116. DOI: 10.3389/fnbeh.2022.1027310.
Huerta Sanchez L, Sankaran M, Li T, Doan H, Chiu A, Shulman E Front Psychiatry. 2023; 13:1031585.
PMID: 36684008 PMC: 9846226. DOI: 10.3389/fpsyt.2022.1031585.
Schwendt M, Knackstedt L Int J Mol Sci. 2021; 22(11).
PMID: 34204090 PMC: 8200945. DOI: 10.3390/ijms22116113.
Chiu A, Kang M, Huerta Sanchez L, Fabella A, Holder K, Barger B Neuropsychopharmacology. 2021; 46(12):2090-2100.
PMID: 34188183 PMC: 8505628. DOI: 10.1038/s41386-021-01064-9.